

ICICI Securities successfully advises Inventia Healthcare Limited on its equity fund raise from India Life Science Fund-III (InvAscent)

ICICI Securities Limited ("I-Sec") is pleased to announce the successful closure of INR. 1,000 Mn equity fund raise in Inventia Healthcare Limited ("Inventia" or the "Company") from India Life Science Fund-III ("InvAscent"), a leading life sciences focused private equity fund with corpus of USD 250 Mn. This is the second round of funding in the Company. The Company had previously raised funding from PE firm Jacob Ballas.



Highlights of the Transaction :

InvAscent will be acquiring minority stake in the Company. The Company will use the proceeds of the fund raise to accelerate growth of its pharma and nutraceutical business and also deleveraging the Balance sheet

- I-Sec acted as the exclusive financial advisor to Inventia for the transaction
- I-Sec provided comprehensive sell-side advisory services to Inventia viz. positioning the opportunity to a curated list of leading life sciences focused investors, advising the Company on the valuation, negotiating the term sheets, assisting in the due diligence process, etc.
- I-Sec successfully convinced the investor on the Company's business model resilience despite the impact of Covid-19;
- I-Sec advised the company on transaction structuring and negotiation of definitive transaction documents
- I-Sec worked closely with the Company, InvAscent, the existing investor and their respective advisors to assist in the seamless execution of the transaction

With this deal completion, ICICI Securities continues to demonstrate its ability to guide its clients through unprecedented times and successfully conclude transactions in challenging environment. It clearly depicts I-Sec capabilities to provide high quality transaction advisory services to reputed and high-growth potential businesses.

About Inventia Healthcare Limited

Inventia is a pharmaceutical development and manufacturing company headquartered in Mumbai with over 30 years of operations. Its focus is on development of value added oral solid dosage formulations ("OSDF"). Over the years, company has developed capabilities in offering end to end solutions in the product development process, right from research and development all the way to final manufacturing and packaging. Company is also venturing into Injectables and Nutraceuticals segments.

Regards,
Ajay Saraf
Executive Director

About ICICI Securities

ICICI Securities Limited (I-Sec) is a subsidiary of ICICI Bank Ltd. The company began its operation in May 1995 and continues to grow its operation through expanding its client base and providing different type of services. I-Sec operates www.icicidirect.com, India's leading virtual financial supermarket, meeting the three need sets of its clients- investments, protection, and borrowing. Through its four lines of businesses - broking, distribution of financial products, wealth management, and investment banking - I-Sec serves customers ranging from the retail and institutional investors to corporates to high net-worth individuals to government. I-Sec is listed on National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE). For details, visit: www.icicisecurities.com

Disclaimer

The information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities Limited. The contents thereof are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. I-Sec and its affiliates accept no liabilities for any loss or damage of any kind arising out of any inaccurate, delayed or incomplete information or for any actions taken in Axis Bank thereon. This information is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject I-Sec and affiliates to any registration or licensing requirement within such jurisdiction

[Unsubscribe](#) from mailing list.